Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors

Breast Cancer Research and Treatment

Volumn 161, Issue 1, 2017, Pages 161-172

  Calip, Gregory S ^a   Elmore, Joann G ^b   Boudreau, Denise M ^b,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer survivorship; Diabetes; Dyslipidemias; Hypertension; Medication adherence

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICATION COMPLIANCE; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; BREAST TUMOR; CANCER REGISTRY; CANCER STAGING; COMPLICATION; DIABETIC COMPLICATION; HEALTH SURVEY; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; SEER PROGRAM; SURVIVORS; YOUNG ADULT;

EID: 84994406577     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-4043-1     Document Type: Article

References (54)

1. Ritchie CS, Kvale E, Fisch MJ (2011) Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract 7(6):371–374. doi:10.1200/JOP.2011.000460
2. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300(23):2754–2764. doi:10.1001/jama.2008.824
3. Calip GS, Yu O, Hoskins KF, Boudreau DM (2015) Associations between diabetes medication use and risk of second breast cancer events and mortality. Cancer Causes Control 26(8):1065–1077. doi:10.1007/s10552-015-0599-z
4. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461–1468. doi:10.1093/jnci/djr291
5. Nickels S, Vrieling A, Seibold P, Heinz J, Obi N, Flesch-Janys D, Chang-Claude J (2013) Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS ONE 8(9):e75088. doi:10.1371/journal.pone.0075088
6. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109(3):573–579. doi:10.1007/s10549-007-9683-8
7. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, Avorn J, Solomon D, Brookhart MA, Choudhry NK (2010) Patient, physician, and payment predictors of statin adherence. Med Care 48(3):196–202. doi:10.1097/MLR.0b013e3181c132ad
8. Steiner JF, Ho PM, Beaty BL, Dickinson LM, Hanratty R, Zeng C, Tavel HM, Havranek EP, Davidson AJ, Magid DJ, Estacio RO (2009) Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes 2(5):451–457. doi:10.1161/CIRCOUTCOMES.108.841635
9. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497. doi:10.1056/NEJMra050100
10. Peyrot M, McMurry JF Jr, Kruger DF (1999) A biopsychosocial model of glycemic control in diabetes: stress, coping and regimen adherence. J Health Soc Behav 40(2):141–158
11. Earle CC, Neville BA (2004) Under use of necessary care among cancer survivors. Cancer 101(8):1712–1719. doi:10.1002/cncr.20560
12. Zanders MM, Haak HR, van Herk-Sukel MP, van de Poll-Franse LV, Johnson JA (2015) Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia 58(5):951–960. doi:10.1007/s00125-015-3497-8
13. Snyder CF, Frick KD, Peairs KS, Kantsiper ME, Herbert RJ, Blackford AL, Wolff AC, Earle CC (2009) Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med 24(4):469–474. doi:10.1007/s11606-009-0903-2
14. Higashi T, Wenger NS, Adams JL, Fung C, Roland M, McGlynn EA, Reeves D, Asch SM, Kerr EA, Shekelle PG (2007) Relationship between number of medical conditions and quality of care. N Engl J Med 356(24):2496–2504. doi:10.1056/NEJMsa066253
15. Min LC, Wenger NS, Fung C, Chang JT, Ganz DA, Higashi T, Kamberg CJ, MacLean CH, Roth CP, Solomon DH, Young RT, Reuben DB (2007) Multimorbidity is associated with better quality of care among vulnerable elders. Med Care 45(6):480–488. doi:10.1097/MLR.0b013e318030fff9
16. American Cancer Society (2013) Breast cancer facts & figures 2013–2014. American Cancer Society Inc., Atlanta
17. Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM (2015) Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf 24(1):75–85. doi:10.1002/pds.3660
18. Calip GS, Boudreau DM, Loggers ET (2013) Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. Breast Cancer Res Treat 138(1):225–233. doi:10.1007/s10549-013-2424-2
19. Santorelli ML, Steinberg MB, Hirshfield KM, Rhoads GG, Bandera EV, Lin Y, Demissie K (2016) Effects of breast cancer on chronic disease medication adherence among older women. Pharmacoepidemiol Drug Saf 25(8):898–907. doi:10.1002/pds.3971
20. Yang J, Neugut AI, Wright JD, Accordino M, Hershman DL (2016) Nonadherence to oral medications for chronic conditions in breast cancer survivors. J Oncol Pract. doi:10.1200/JOP.2016.011742
21. Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS (2014) Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 144(2):405–416. doi:10.1007/s10549-014-2870-5
22. Surveillance Epidemiology and End Results (SEER) program overview of the SEER program http://seer.cancer.gov/about/overview.html
23. Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 223–239
24. Washington State Department of Health, Center for Health Statistics. Death Data. http://www.doh.wa.gov/DataandStatisticalReports/VitalStatisticsData/DeathData. Accessed 15 Jun 2011
25. Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565–574. doi:10.1002/pds.1230
26. Bryson CL, Au DH, Young B, McDonell MB, Fihn SD (2007) A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care 45(6):497–504. doi:10.1097/MLR.0b013e3180329368
27. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, Solomon DH (2009) Measuring concurrent adherence to multiple related medications. Am J Manag Care 15(7):457–464
28. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619
29. Steiner JF (2016) Measuring adherence with medications: time is of the essence. Pharmacoepidemiol Drug Saf 25(3):333–335. doi:10.1002/pds.3932
30. Lau DT, Nau DP (2004) Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 27(9):2149–2153
31. Hepke KL, Martus MT, Share DA (2004) Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 10(2 Pt 2):144–151
32. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, Burton CM, Evans M (2012) The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 35(6):1279–1284. doi:10.2337/dc11-1277
33. Raebel MA, Ellis JL, Carroll NM, Bayliss EA, McGinnis B, Schroeder EB, Shetterly S, Xu S, Steiner JF (2012) Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med 27(1):57–64. doi:10.1007/s11606-011-1829-z
34. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J (1996) Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health 86(12):1805–1808
35. Janz NK, Becker MH (1984) The Health Belief Model: a decade later. Health Educ Q 11(1):1–47
36. Olson KL, Rasmussen J, Sandhoff BG, Merenich JA, Clinical Pharmacy Cardiac Risk Service Study G (2005) Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med 165(1):49–54. doi:10.1001/archinte.165.1.49
37. McCulloch DK, Price MJ, Hindmarsh M, Wagner EH (1998) A population-based approach to diabetes management in a primary care setting: early results and lessons learned. Eff Clin Pract 1(1):12–22
38. Kantsiper M, McDonald EL, Geller G, Shockney L, Snyder C, Wolff AC (2009) Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med 24(Suppl 2):S459–S466. doi:10.1007/s11606-009-1000-2
39. Peairs KS, Wolff AC, Olsen SJ, Bantug ET, Shockney L, Kantsiper ME, Carrino-Tamasi E, Snyder CF (2011) Coordination of care in breast cancer survivors: an overview. J Support Oncol 9(6):210–215. doi:10.1016/j.suponc.2011.06.008
40. Hewitt ME, Ganz PA, Institute of Medicine (U.S.), American Society of Clinical Oncology (U.S.) (2006) From cancer patient to cancer survivor: lost in transition. National Academies Press, Washington
41. Bayliss EA, Blatchford PJ, Newcomer SR, Steiner JF, Fairclough DL (2011) The effect of incident cancer, depression and pulmonary disease exacerbations on type 2 diabetes control. J Gen Intern Med 26(6):575–581. doi:10.1007/s11606-010-1600-x
42. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375(9710):181–183. doi:10.1016/S0140-6736(09)61794-3
43. Mozumdar A, Liguori G (2011) Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care 34(1):216–219. doi:10.2337/dc10-0879
44. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, Giugliano D (2013) Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 20(12):1301–1309. doi:10.1097/GME.0b013e31828ce95d
45. Calip GS, Malone KE, Gralow JR, Stergachis A, Hubbard RA, Boudreau DM (2014) Metabolic syndrome and outcomes following early-stage breast cancer. Breast Cancer Res Treat 148(2):363–377. doi:10.1007/s10549-014-3157-6
46. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S (2006) Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119(1):236–238. doi:10.1002/ijc.21812
47. Berrino F, Villarini A, Traina A, Bonanni B, Panico S, Mano MP, Mercandino A, Galasso R, Barbero M, Simeoni M, Bassi MC, Consolaro E, Johansson H, Zarcone M, Bruno E, Gargano G, Venturelli E, Pasanisi P (2014) Metabolic syndrome and breast cancer prognosis. Breast Cancer Res Treat 147(1):159–165. doi:10.1007/s10549-014-3076-6
48. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT, Whelton PK Jr, Group SSR (2014) The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 11(5):532–546. doi:10.1177/1740774514537404
49. American Diabetes Association (2015) Standards of medical care in diabetes–2015. Diabetes Care 38(Suppl 1):S1–S98. doi:10.2337/dc15-S001
50. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–520. doi:10.1001/jama.2013.284427
51. Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice G (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63(25 Pt B):2889–2934. doi:10.1016/j.jacc.2013.11.002
52. Boudreau DM, Doescher MP, Jackson JE, Fishman PA, Saver BG (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38(7–8):1317–1318. doi:10.1345/aph.1D569
53. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2(2):CD000011. doi:10.1002/14651858.CD000011.pub3
54. Group Health Breast Cancer Surveillance Registry. http://www.grouphealthresearch.org/surveillanceproject. Accessed 15 Jun 2011